NASHVILLE, Tenn., Jan. 13, 2026 /PRNewswire/ -- Revance and Teoxane announce the FDA approval of RHA ® Dynamic Volume from the Teoxane RHA ® Collection for cheek augmentation and/or the correction of ...
"The development of the Teoxane RHA ® Collection with Mepivacaine exemplifies Teoxane's commitment to innovation," states Valérie Taupin, Founder and CEO of Teoxane. "Mepivacaine represents the first ...
Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that its data will be ...
Teoxane today announced the publication in the Aesthetic Surgery Journal of a pivotal randomized, controlled, double-blinded trial evaluating the safety and effectiveness of RHA® 3 for lip ...
- Supports Revance’s commitment to ensuring safety and efficacy of aesthetic product portfolio among diverse patient populations - NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results